Sharekhan's research report on Insecticides India
Revenues stood at Rs. 627 crore, down 10% y-o-y and 5% q-o-q, 12% below our estimates. EBITDA came in at Rs. 90 crore, marking a 29% y-o-y increase but a 1% decline q-o-q, beating estimates by 7%. Margins were at 14%, rising by 251 bps y-o-y and 339 bps q-o-q. PAT stood Rs. 61 crore, up 47% y-o-y and 19% q-o-q, surpassing estimates by 8%.
Outlook
We retain a Buy rating with a revised PT of Rs. 949. Valuation of 19x/16x its FY2025E/FY2026E EPS is deemed justified.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
